Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Balance Impairment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Balance Impairment. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000562-21 Sponsor Protocol Number: L00014 CP 201 Start Date*: 2007-09-19
    Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF
    Full Title: Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly.
    Medical condition: Postural disturbances in the elderly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049848 Balance disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001545-25 Sponsor Protocol Number: CHDR1409 Start Date*: 2014-07-02
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys...
    Medical condition: Healthy volunteers (balance disorders)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10049848 Balance disorder PT
    17.0 10029205 - Nervous system disorders 10004070 Balance difficulty LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002011-61 Sponsor Protocol Number: 77267 Start Date*: 2021-08-13
    Sponsor Name:Academisch ziekenhuis Maastricht
    Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
    Medical condition: 22q11.2 deletion syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004685-17 Sponsor Protocol Number: ERA2005neuro Start Date*: 2005-11-16
    Sponsor Name:CUB - Hôpital Erasme
    Full Title: A prospective placebo controlled study of botulilium toxin (BOTOX) on gait disorder induced by spastic equinovarus foot.
    Medical condition: Spastic equinus foot is a common dynamic deformity in patients with cerebral palsy. This dynamic deformity, mainly caused by spasticity of the soleus, gastrocnemius and tibialis posterior muscles, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003747-31 Sponsor Protocol Number: 523001.01.071 Start Date*: 2005-12-27
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Parallel Group Trial to Confirm the Efficacy, Safety and Tolerability of Ginkgo biloba Special Extract EGb 761® in Patients Suffering from Mild Mental ...
    Medical condition: mild mental impairment
    Disease: Version SOC Term Classification Code Term Level
    10027374
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-001902-10 Sponsor Protocol Number: 2006/168 Start Date*: 2006-05-31
    Sponsor Name:Kirurgisk Forskningsafsnit, Herning Sygehus
    Full Title: Effects of caffeine on people suffering from intermittens claudication. Three double blinded, placebo-controlled cross-over studies and a follow-up study.
    Medical condition: Intermittens claudication, peripheral arterial disease (PAD) Atherosclerotic disease of the lower extremities
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004350-91 Sponsor Protocol Number: TAK-375/EC301 Start Date*: 2005-11-10
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with...
    Medical condition: chronic insomnia
    Disease: Version SOC Term Classification Code Term Level
    8 10053851 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000303-28 Sponsor Protocol Number: MW029 Start Date*: 2014-09-29
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for ...
    Medical condition: Presby Vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004122-18 Sponsor Protocol Number: 2012GR12 Start Date*: 2014-12-12
    Sponsor Name:University of Dundee, Tayside Clinical Trials Unit
    Full Title: A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Older People with Impaired Physical Function.
    Medical condition: FUNCTIONAL IMPAIRMENT
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10065629 Decreased exercise endurance LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-001104-33 Sponsor Protocol Number: AT0071002 Start Date*: 2023-12-22
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients with Classic Galactosemia (CG)
    Medical condition: Galactosemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017610 Galactosemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-001512-38 Sponsor Protocol Number: EPU-P87 Start Date*: 2016-10-10
    Sponsor Name:Maastricht University
    Full Title: Investigation of psychomotor performance to evaluate clinical impairment and pharmacokinetic aspects of methadone and buprenorphine: a double-blind placebo-controlled randomized trial
    Medical condition: None
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000902-37 Sponsor Protocol Number: RH-ITA-005 Start Date*: 2014-06-27
    Sponsor Name:Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet
    Full Title: Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003600-40 Sponsor Protocol Number: 218MS305 Start Date*: 2014-09-15
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects w...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) CZ (Completed) IT (Completed) FI (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004758-27 Sponsor Protocol Number: IVIGPANSOpen Start Date*: 2020-03-02
    Sponsor Name:Gillberg Neuropsychiatry Centre
    Full Title: Intravenous immunoglobulin (IVIG) treatment in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS): an open-label trial in South-western Sweden
    Medical condition: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsions and...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024087-17 Sponsor Protocol Number: MAG104615 Start Date*: 2011-11-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003053-25 Sponsor Protocol Number: 1466 Start Date*: 2012-06-18
    Sponsor Name:Research and Enterprise Department
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013702-14 Sponsor Protocol Number: BETNV009 Start Date*: 2010-08-13
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial
    Medical condition: vestibular failure (vestibular neuritis)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10047386 Vestibular disorder PT
    18.0 10029205 - Nervous system disorders 10029240 Neuritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004832-48 Sponsor Protocol Number: GN19CA407 Start Date*: 2020-12-17
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controll...
    Medical condition: Diuretic resistant heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    20.0 100000004849 10066159 Decompensated heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    20.0 10042613 - Surgical and medical procedures 10053073 Diuretic therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002162-30 Sponsor Protocol Number: HC-G-H-1504 Start Date*: 2017-04-12
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients u...
    Medical condition: Hypovolaemia due to acute blood loss in elective abdominal surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10021137 Hypovolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) ES (Restarted) FR (Ongoing) AT (Completed) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-002502-74 Sponsor Protocol Number: NEU-01-02-01 Start Date*: 2012-02-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA